These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27716785)

  • 1. Using Rich Data on Comorbidities in Case-Control Study Design with Electronic Health Record Data Improves Control of Confounding in the Detection of Adverse Drug Reactions.
    Backenroth D; Chase H; Friedman C; Wei Y
    PLoS One; 2016; 11(10):e0164304. PubMed ID: 27716785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empirical performance of the case-control method: lessons for developing a risk identification and analysis system.
    Madigan D; Schuemie MJ; Ryan PB
    Drug Saf; 2013 Oct; 36 Suppl 1():S73-82. PubMed ID: 24166225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.
    Schuemie MJ; Gini R; Coloma PM; Straatman H; Herings RM; Pedersen L; Innocenti F; Mazzaglia G; Picelli G; van der Lei J; Sturkenboom MC
    Drug Saf; 2013 Oct; 36 Suppl 1():S159-69. PubMed ID: 24166232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system.
    Norén GN; Bergvall T; Ryan PB; Juhlin K; Schuemie MJ; Madigan D
    Drug Saf; 2013 Oct; 36 Suppl 1():S107-21. PubMed ID: 24166228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system.
    Suchard MA; Zorych I; Simpson SE; Schuemie MJ; Ryan PB; Madigan D
    Drug Saf; 2013 Oct; 36 Suppl 1():S83-93. PubMed ID: 24166226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the empirical performance of methods for a risk identification system.
    Ryan PB; Stang PE; Overhage JM; Suchard MA; Hartzema AG; DuMouchel W; Reich CG; Schuemie MJ; Madigan D
    Drug Saf; 2013 Oct; 36 Suppl 1():S143-58. PubMed ID: 24166231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series.
    Schuemie MJ; Trifirò G; Coloma PM; Ryan PB; Madigan D
    Stat Methods Med Res; 2016 Dec; 25(6):2577-2592. PubMed ID: 24685766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A method for controlling complex confounding effects in the detection of adverse drug reactions using electronic health records.
    Li Y; Salmasian H; Vilar S; Chase H; Friedman C; Wei Y
    J Am Med Inform Assoc; 2014; 21(2):308-14. PubMed ID: 23907285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MetaLAB-HOI: Template standardization of health outcomes enable massive and accurate detection of adverse drug reactions from electronic health records.
    Lee S; Shin H; Choe S; Kang MG; Kim SH; Kang DY; Kim JH
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5694. PubMed ID: 37710363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs.
    Lin KJ; Schneeweiss S
    Clin Pharmacol Ther; 2016 Aug; 100(2):147-59. PubMed ID: 26916672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal Detection for Recently Approved Products: Adapting and Evaluating Self-Controlled Case Series Method Using a US Claims and UK Electronic Medical Records Database.
    Zhou X; Douglas IJ; Shen R; Bate A
    Drug Saf; 2018 May; 41(5):523-536. PubMed ID: 29327136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of disproportionality safety signaling applied to healthcare databases.
    DuMouchel W; Ryan PB; Schuemie MJ; Madigan D
    Drug Saf; 2013 Oct; 36 Suppl 1():S123-32. PubMed ID: 24166229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining a reference set to support methodological research in drug safety.
    Ryan PB; Schuemie MJ; Welebob E; Duke J; Valentine S; Hartzema AG
    Drug Saf; 2013 Oct; 36 Suppl 1():S33-47. PubMed ID: 24166222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of adverse drug reactions using hospital databases-a nationwide study in Portugal.
    Miguel A; Bernardo Marques ; Freitas A; Lopes F; Azevedo L; Pereira AC
    Pharmacoepidemiol Drug Saf; 2013 Aug; 22(8):907-13. PubMed ID: 23761351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection.
    Pacurariu AC; Straus SM; Trifirò G; Schuemie MJ; Gini R; Herings R; Mazzaglia G; Picelli G; Scotti L; Pedersen L; Arlett P; van der Lei J; Sturkenboom MC; Coloma PM
    Drug Saf; 2015 Dec; 38(12):1201-10. PubMed ID: 26370104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.
    Reich CG; Ryan PB; Suchard MA
    Drug Saf; 2013 Oct; 36 Suppl 1():S195-204. PubMed ID: 24166235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative outcome definitions and their effect on the performance of methods for observational outcome studies.
    Reich CG; Ryan PB; Schuemie MJ
    Drug Saf; 2013 Oct; 36 Suppl 1():S181-93. PubMed ID: 24166234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system.
    Schuemie MJ; Madigan D; Ryan PB
    Drug Saf; 2013 Oct; 36 Suppl 1():S133-42. PubMed ID: 24166230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structured assessment for prospective identification of safety signals in electronic medical records: evaluation in the health improvement network.
    Cederholm S; Hill G; Asiimwe A; Bate A; Bhayat F; Persson Brobert G; Bergvall T; Ansell D; Star K; Norén GN
    Drug Saf; 2015 Jan; 38(1):87-100. PubMed ID: 25539877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.